GENESIS-PHARMA
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare announces CE Mark for new digital 4D SPECT/CT system, StarGuide GX27.11.2025 12:06:00 CET | Press release
FOR USE IN CE-MARK EUROPEAN COUNTRIES ONLY StarGuide GXi empowers personalized care and research innovation as nuclear medicine expands into new applications The system doubles volume sensitivity,ii maintains high resolution and enables clinicians to virtually scan all energies fast – including the acquisition of investigational alpha emitters like Actinium-225 – with exceptional clarity and quantitation GE HealthCare today announced CE Mark for its new StarGuide™ GX system,i a new digital 4D SPECT/CT designed with excellent precision, clinical efficiency and impressive versatility. This milestone marks a significant moment in molecular imaging’s evolution, helping empower clinicians to expand research and help personalize care across a growing range of nuclear medicine applications and tracers – including the acquisition of alpha emitters. StarGuide GX comes at a pivotal time for the field of nuclear medicine. As complex diseases such as cancer, Alzheimer’s and cardiovascular disease
Deetken Impact Expands Climate Finance Leadership as Canada Joins Inclusive Climate Action Fund27.11.2025 10:07:00 CET | Press release
Deetken Impact, a Canadian impact investment firm, is proud to partner with the Government of Canada and announce their CAD$106 million commitment in the new Inclusive Climate Action Fund (ICAF), a USD$300 million blended finance vehicle that will mobilize capital for climate finance initiatives across Latin America and the Caribbean (LAC). Announced at the 30th United Nations Climate Change Conference (COP30) in Belém, Brazil by the Honourable Julie Dabrusin, Canada’s Minister of Environment and Climate Change, ICAF will meaningfully contribute to sustainable and climate-resilient economies in LAC through the strategic provision of capital and technical assistance to companies and projects that drive climate mitigation and adaptation in key sectors such as clean energy, sustainable agriculture and agroforestry, and green finance. ICAF aims to achieve ambitious impacts including reducing, avoiding, or sequestering more than 5 million tCO2 and expanding access to climate solutions for 1
Infobip Unveils 2026 Trends Poised to Transform Customer Engagement and Digital Ecosystems27.11.2025 10:00:00 CET | Press release
AI automation, Rich Messaging and platform integration set to reshape industries Global cloud communications platform Infobip today announces its predictions for 2026, spotlighting transformative trends set to redefine how businesses engage customers and operate across sectors. Central to these shifts are the mainstream adoption of AI-powered agents, the expansion of super apps as integrated ecosystems, and the rise of privacy-first AI models enabling scalable, compliant automation. “2026 will be a breakthrough year as generative AI and omnichannel communication converge to redefine customer engagement and digital ecosystems,”said Silvio Kutić, CEO at Infobip. “Retail and eCommerce sectors are already leading the way with hyper-personalized experiences, while healthcare and finance are rapidly adopting AI-driven solutions to enhance patient care and security. Crucially, the future of customer service lies in a human-in-the-loop approach—where AI-powered automation works hand-in-hand wi
Lenovo Leads the Circular IT Shift with a New Chapter to Extend Lifecycles for Aging Tech27.11.2025 09:27:00 CET | Press release
Lenovo Certified Refurbishment Services, now live across 14 European markets, help businesses reduce e-waste and stretch IT investments further Lenovo today introduced Lenovo Certified Refurbishment Services, a new addition to its IT sustainability and lifecycle solutions portfolio, available in EMEA. The service gives organizations the ability to refurbish their existing Lenovo devices, restoring useful life and enabling redeployment to deliver cost savings, maximize IT budgets and reduce e-waste. Most businesses still follow a binary model for their device lifecycle and refresh strategies: extend the warranty or buy new. However, Lenovo’s Certified Refurbishment Services introduce a powerful third option, refurbishing existing Lenovo devices to be reused or repurposed internally, to avoid premature retirements, balance IT refresh programs and help maximize investment. With IT budgets under pressure and sustainability goals rising to the top of corporate agendas, businesses across Eur
Hytera Introduces Smart PoC Radios P50E and P60 at PMRExpo 202527.11.2025 09:00:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, has officially launched its latest smart Push-to-Talk over Cellular (PoC) radios – the P50E and the P60 – at PMRExpo 2025. This launch marks a significant expansion of Hytera’s PoC portfolio, delivering the company’s most robust and comprehensive range of devices to date, offering a wide spectrum of options to meet the growing demand for PoC solutions across all sectors throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126296378/en/ Hytera unveiled new PoC radios P50E & P60 at PMRExpo 2025. Stay Smart and Safe with the P50E Featuring a compact 0.96-inch screen and a keyboard-free design, the P50E embodies the design philosophy of the P5 Series – Where Reliability Meets Simplicity. With the addition of the P50E, the P5 Series – which also includes the P50 and the P50 Pro – now provides users greater flexibility to align
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom